Skip to main content
Premium Trial:

Request an Annual Quote

NanoInk Places Dip Pen Nanolithography System at U of Strathclyde

Premium

By Justin Petrone

NanoInk this week announced the delivery of its DPN 5000 benchtop array fabrication system to researchers at the University of Strathclyde in the UK.

Skokie, Ill.-based NanoInk launched the DPN 5000 last year. The nanofabrication system combines nanopatterning capabilities with atomic force microscopy imaging and a suite of micro-electromechanical systems-based ink delivery devices. The system is based on NanoInk's Dip Pen Nanolithography approach to nanofabrication, where materials are deposited onto a surface via a sharp probe tip.

U of Strathclyde's Duncan Graham and colleagues at the Centre for Molecular Nanometrology will use the system for in vivo imaging approaches based on functional nanoparticles and surface enhanced Raman spectroscopy analysis, NanoInk said.

Graham is a longtime collaborator of the firm and has used its technology to create nanoscale arrays of biomolecules, nanoparticles, and self-assembled monolayer molecules. Graham has also used NanoInk's technology to develop protein assays, according to the firm.

Financial details of the placement were not discussed.

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.